2024
1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
Warner A, Smithy J, Los C, Kalvin H, Hasson N, Amaria R, Czapla J, Schollenberger M, furness A, Hassel J, Wermke M, Gallegos J, Lutzky J, Lipson E, Sullivan R, Kluger H, Panageas K, Klobuch S, Haanen J, Shoushtari A. 1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma. Annals Of Oncology 2024, 35: s730-s731. DOI: 10.1016/j.annonc.2024.08.1170.Peer-Reviewed Original Research
2019
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
Sarnaik A, Khushalani N, Chesney J, Kluger H, Curti B, Lewis K, Thomas S, Whitman E, Hamid O, Lutzky J, Pavlick A, Weber J, Larkin J, Barton D, Yung L, Suzuki S, Fardis M, Kirkwood J. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. Journal Of Clinical Oncology 2019, 37: 2518-2518. DOI: 10.1200/jco.2019.37.15_suppl.2518.Peer-Reviewed Original ResearchBRAF/MEK inhibitorsTumor-infiltrating lymphocytesMetastatic melanoma patientsMelanoma patientsTIL therapyPrior therapyAdvanced metastatic melanoma patientsDurable long-term responsesMEK inhibitorsBaseline tumor burdenCohort 2 patientsMultiple prior therapiesTIL infusion productsIL-2 dosesAdoptive cell therapyUnresectable metastatic melanomaBaseline disease burdenOverall disease controlAutologous tumorTIL infusionTIL productionMedian followCheckpoint inhibitorsUnresectable melanomaAdverse events
2010
A phase 2 trial of dasatinib in advanced melanoma
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2010, 117: 2202-2208. PMID: 21523734, PMCID: PMC3116034, DOI: 10.1002/cncr.25766.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-kit mutationsPhase 2 trialResponse ratePartial responseMedian progression-free survivalMelanoma cell proliferationDaily dasatinibMucosal primaryPFS ratesStarting dosageCommon toxicitiesUnresectable melanomaAdvanced melanomaPleural effusionMelanoma patientsPredictive biomarkersMinor responseCombination trialsTumor assessmentDose reductionPatientsPrespecified endpointsDasatinibMelanoma
2009
A phase II trial of dasatinib in advanced melanoma
Kluger H, Dudek A, McCann C, Rink L, Ritacco J, Adrada C, Phouyaphone N, Southard N, Sznol M. A phase II trial of dasatinib in advanced melanoma. Journal Of Clinical Oncology 2009, 27: 9010-9010. DOI: 10.1200/jco.2009.27.15_suppl.9010.Peer-Reviewed Original ResearchStarting dosePartial responseC-kitNon-cytotoxic therapiesPhase 2 trialPhase II trialSubset of patientsMelanoma cell proliferationCommon toxicitiesDaily dasatinibMucosal primaryPo bidPrior chemotherapyII trialClinical responseUnresectable melanomaAdvanced melanomaMedian agePleural effusionMinor responseGrade IITumor assessmentDose reductionPreclinical evaluationPatients